Dorsey Wright & Associates Chemo Centryx, Inc. Transaction History

Dorsey Wright & Associates

$376 Million
Q2 2024

Shares

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2019 Jul 02, 2019	SELL	$8.31 - $14.85 $4,861 - $8,687	-585 Closed	0 $0
Q1 2019 Apr 04, 2019	SELL	$10.01 - $13.89 $5,855 - $8,125	-585 Reduced 50.0%	585 $8,000
Q4 2018 Jan 07, 2019	BUY	$9.15 - $12.26 $1,784 - $2,390	195 Added 20.0%	1,170 $13,000
Q3 2018 Oct 12, 2018	BUY	$10.49 - $13.72 $10,227 - $13,377	975 New	975 $12,000

Others Institutions Holding CCXI

# of Institutions

6

Shares Held

66.3K

Call Options Held

0

Put Options Held

0

About ChemoCentryx, Inc.

Ticker CCXI
Exchange NASDAQ
Shares Outstandng 71,919,696
Market Cap $3.68M
Description
ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil...

More about CCXI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Dorsey Wright & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Dorsey Wright & Associates with notifications on news.